Vytorin: Impact of the ENHANCE Trial
A Survey of One Hundred and Eight Primary Care Physicians and Cardiologists
Deliverable: Survey with key findings.
Study Description:
|
Topic |
Impact of ENHANCE Trial on Vytorin and Zetia Prescribing |
|
Respondent Type |
Physicians |
|
Specialties Covered |
Primary Care, Internal Medicine, General Practice, Cardiology |
|
Region |
United States Only |
|
Methodology |
Online survey, self-administered via a Panel Intelligence website Duration: 10 minutes Size: 108 respondents Fielding Dates: Jan 17, 2008 to Jan 18, 2008 |
Objective:
To understand the market impact of the ENHANCE trial on Vytorin and Zetia.
Companies and Products Mentioned in This Report:
|
Company |
Ticker Symbol |
Product(s) |
|
AstraZeneca |
AZN |
Crestor |
|
Pfizer |
PFE |
Lipitor |
|
Merck/Schering-Plough Pharmaceuticals |
MRK/SGP |
Vytorin |
|
Merck/Schering-Plough Pharmaceuticals |
MRK/SGP |
Zetia |
|
Merck & Co |
MRK |
Zocor |
Inclusion Criteria:
|
Inclusion Criteria |
§ Primary Care Physicians including Internists and General Practitioners (N=78) § General/Medical Cardiologists (N=30) § In practice between 2 and 30 years § Spends at least 75% of professional time in clinical practice § Writes at least 20 Vytorin and Zetia (combined) scripts per month |
Print Abstract
For additional information on this study or to purchase, please call:
|
Survey
Cardiology |